alexa
Reach Us +44-1647-403003
The Use of Nanocarriers for Drug Delivery in Cancer Therapy | OMICS International | Abstract
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

The Use of Nanocarriers for Drug Delivery in Cancer Therapy

David R. Khan*

Department of Mathematics, Chemistry and Physics, West Texas A&M University, Canyon, TX 79016-0001, USA

*Corresponding Author:
Dr. David R. Khan,
Department of Mathematics, Chemistry and Physics,
West Texas A&M University,
Canyon, TX 79016-0001,
Tel: 806-651-2547,
Fax: 806-651-2544,
Email: [email protected]

Received Date: April 04, 2010; Accepted Date: May 10, 2010; Published Date:May 10, 2010

Citation: Khan DR (2010) The use of Nanocarriers for Drug Delivery in Cancer Therapy. J Cancer Sci Ther 2: 058-062. doi:10.4172/1948-5956.1000024

Copyright: © 2010 Khan DR. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

The use of nanocarriers as drug delivery systems for chemotherapeutic agents can improve the overall pharmacological properties of commonly used drugs in chemotherapy. The clinical success, as well as the ease with which surface modifi cations can be made to both liposomes and micelles to accommodate targeting ligands have made these nanocarriers in particular attractive candidates for future work involving targeted drug delivery. Although not targeted, there are clinically approved liposomal-based drugs that are currently used to treat various types of cancers. Furthermore, there are several other formulations involving both of these nanocarriers which are now in various stages of clinical trials. This review discusses the use of liposomes and micelles in cancer therapy and attempts to provide some current information regarding the clinical status of several of these nanocarrier-based drugs. In addition, recent work involving the incorporation of targeting ligands to systems such as these in order to improve colocalization between the drug and cancer cells is also addressed. Furthermore, while the use of these nanocarriers in particular is the primary focus here, this review also contains a discussion on other commonly used nanocarriers in cancer therapy to include various polymer-based and polymer-protein conjugates. Finally, the possibility of using combinatorial approaches involving multiple surface modifi cations made to both liposomes and micelles in order to further improve their drug delivery capabilities is also discussed.

Keywords

Recommended Conferences
Share This Page
Top